Arrendondo 1997.

Methods	Randomised, double‐blind, placebo‐controlled, parallel two‐arm trial
Participants	Country: USA Site: No details Recruitment: 72 women no other details Refer to table of bias for details of attrition Inclusion: Meeting defined criteria for PMS using Penn Daily Symptom Report (DSR) for two cycles. Regular menstrual cycles (22‐35 days), general good health Exclusion: No current major psychiatric diagnoses as assessed by Structured Clinical Interview (SCID) No explicit exclusion criteria noted
Interventions	Screening: Screening for two cycles Placebo run‐in: None Interventions: Placebo (n=35) versus sertraline 50mg administered orally (n=37) Duration: Treatment administered for three cycles Timing of administration: No details of when in the cycle this was first administered Summary measures: Data presented as individual treatment cycles. Review has used mean data across all three cycles
Outcomes	Penn Daily Self Rating Symptoms (DSR). Depression and food craving scores. Depression score reported in current review
Notes	Only available as abstract Daily recording of symptoms Measured depression and food cravings No details of ITT or power calculation No details of funding source
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	States randomised. Method not reported
Allocation concealment (selection bias)	Unclear risk	Method not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	States double blind. No further details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	72 women randomised, number analysed not reported
Selective reporting (reporting bias)	Unclear risk	Adverse effects not reported
Other bias	Unclear risk	Few details available as not published in full text